Full Press Release Details
PainReform Welcomes Successful Healthcare
and Capital Markets Executive
Dr. Ellen Baron to Board of Directors
November 11, 2020 - PainReform Ltd. (NasdaqCM: PRFX) ("PainReform" or the "Company"), a clinical-stage
specialty pharmaceutical company focused on the reformulation of established therapeutics, welcomes Dr. Ellen Baron as a member
of the Company's Board of Directors following its recent initial public offering.
Dr. Ellen Baron has been
a Managing Director at Outcome Capital LLC, a specialized life science and technology strategic advisory and investment banking
firm, since February 2017, serving as global head of the Biopharmaceutical practice. From 2012-2017, she served as a Managing Director
of Healthios Capital Markets, LLC. Before joining Healthios, Dr. Baron served as Lifescience Venture Capital Partner at Oxford
Bioscience Partners and as Senior Vice President, Business Development at Human Genome Sciences, a publicly traded biopharmaceutical
company. Dr. Baron previously spent 20 years at Schering-Plough Corporation in both research and development, as well as business
development. Dr. Baron currently serves on the Board of Directors of Tetragenetics Inc., a biotech company, Sixth Element Capital,
UK-based oncology focused venture capital fund, and SFH, a Maine-based nutraceutical company. Dr. Baron holds a Ph.D. in Microbiology
from Georgetown University School of Medicine, a post-doctorate at the Public Health Research Institute in New York and a bachelor's
degree from Goucher College.
Geller, Chairman of the Board, commented, "I am pleased to welcome Dr. Ellen Baron to our board, as she brings extensive
experience and a successful track record in both the healthcare industry and capital markets. Ellen has proven value as a strategic
advisor with exceptional business acumen and interpersonal skills, deep healthcare industry expertise and relationships, and financial
acumen. She has been instrumental in financing life science companies and has deep domain expertise across multiple disciplines
in the pharmaceutical and biotechnology industries. In addition, her clinical expertise and background in business development
will be important as we advance our planned Phase 3 trial, plan our commercialization activities and seek out potential strategic
partners. We remain highly encouraged by the outlook for the business and look forward to her contributions as we execute on our
mission to bring PRF-110 to market, which we believe has the potential to become standard of care within the multi-billion dollar
post-operative pain market."
PainReform is a clinical-stage specialty pharmaceutical
company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product, is based on the local
anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that
is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia.
The Company's proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical
pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates.
Notice Regarding Forward-Looking Statements
This press release contains certain forward-looking
statements, including statements with regard to PainReform's proposed clinical trials. Words such as "expects,"
"anticipates" and "intends" or similar expressions are intended to identify forward-looking statements.
These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance
can be given that the clinical trials discussed above will be successfully completed. Completion of the proposed clinical trials
are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, failure of
the clinical trials, and the risk factors and other matters set forth in the Company's recent prospectus included in the
registration statement, in the form last filed with the SEC. PainReform undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Crescendo Communications, LLC
Email: prfx@crescendo-ir.com